reported a loss of MLH1 protein in patients after chemotherapy (5), which raised the intriguing question of whether MSS/pMMR CRC could be converted into MSI/dMMR CRC, thus overcoming primary resistance to immunotherapy. This evidence concerns the gene MLH1 and colorectal carcinoma.